Last reviewed · How we verify
Lenalidomide and Dexamethasone
Lenalidomide enhances immune cell activity and has anti-angiogenic properties, while dexamethasone provides anti-inflammatory and immunosuppressive effects to manage multiple myeloma.
Lenalidomide enhances immune cell activity and has anti-angiogenic properties, while dexamethasone provides anti-inflammatory and immunosuppressive effects to manage multiple myeloma. Used for Multiple myeloma (newly diagnosed or relapsed/refractory), Light chain myeloma.
At a glance
| Generic name | Lenalidomide and Dexamethasone |
|---|---|
| Also known as | In the initial 4 cycles of therapy, pts will receive oral lenalidomide at the, starting dose of 25mg on days 1-21 every 28 days (one cycle) with dose, adjustments for creatinine clearance and dose reductions. Pts will receive, low-dose oral dexamethasone at 40mg weekly on days 1, 8, 15 & 22 of each, 28-day cycle with dose reductions (the weekly dose could be split over 2 days |
| Sponsor | HuniLife Biotechnology, Inc. |
| Drug class | Immunomodulatory agent + corticosteroid combination |
| Target | Cereblon (CRBN), TNF-α pathway; glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lenalidomide is an immunomodulatory agent that stimulates T-cell proliferation, enhances natural killer cell activity, and inhibits tumor necrosis factor-alpha production. Dexamethasone is a corticosteroid that provides additional anti-inflammatory and anti-tumor effects. Together, they work synergistically to suppress malignant plasma cell growth and enhance anti-tumor immunity in multiple myeloma.
Approved indications
- Multiple myeloma (newly diagnosed or relapsed/refractory)
- Light chain myeloma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Constipation
- Neuropathy
- Infection
- Hyperglycemia
Key clinical trials
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (PHASE3)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
- A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant (PHASE3)
- A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma (PHASE3)
- A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (PHASE2, PHASE3)
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (PHASE2)
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lenalidomide and Dexamethasone CI brief — competitive landscape report
- Lenalidomide and Dexamethasone updates RSS · CI watch RSS
- HuniLife Biotechnology, Inc. portfolio CI